Stifel Nicolaus started coverage on shares of Urogen Pharma (NASDAQ:URGN) in a report issued on Thursday morning, The Fly reports. The firm issued a buy rating and a $70.00 price objective on the stock.
A number of other equities analysts also recently issued reports on URGN. Oppenheimer set a $75.00 price target on shares of Urogen Pharma and gave the company a buy rating in a report on Tuesday, August 14th. Cowen reiterated a buy rating on shares of Urogen Pharma in a report on Tuesday, August 14th. Finally, ValuEngine upgraded shares of Urogen Pharma from a hold rating to a buy rating in a report on Saturday, June 2nd. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $59.60.
Shares of URGN opened at $46.16 on Thursday. Urogen Pharma has a 52-week low of $25.56 and a 52-week high of $69.57.
Large investors have recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Urogen Pharma during the 2nd quarter valued at about $129,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the 1st quarter valued at about $174,000. UBS Group AG increased its holdings in Urogen Pharma by 31.5% during the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock valued at $180,000 after acquiring an additional 865 shares in the last quarter. DAFNA Capital Management LLC purchased a new position in Urogen Pharma during the 1st quarter valued at about $224,000. Finally, Jane Street Group LLC purchased a new position in Urogen Pharma during the 2nd quarter valued at about $227,000. Hedge funds and other institutional investors own 71.11% of the company’s stock.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: Intrinsic Value
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.